ArticleThe Journal of clinical endocrinology and metabolism2013
Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy.
Article in The Journal of clinical endocrinology and metabolism, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 3 syntheses or guidelines pooled it, 217 citations in OpenAlex.
- Hürthle Cell Carcinoma of the Thyroid Gland: Systematic Review and Meta-analysis.Advances in therapy · 2021Pooled it
- Gene Expression (mRNA) Markers for Differentiating between Malignant and Benign Follicular Thyroid Tumours.International journal of molecular sciences · 2017Pooled it
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.Thyroid : official journal of the American Thyroid Association · 2016Guideline
- Cytologic and Surgical Correlation ofInternational journal of surgical pathology · 2026Article
- Review
- Establishment of a nomogram model for predicting distant metastasis in oncocytic thyroid carcinoma: A retrospective cohort study.Medicine · 2026Article
- Comparison of Oncocytic and Follicular Carcinoma of the Thyroid Without Initial Distant Metastasis.World journal of surgery · 2025Article
- Impact of Reclassification of Oncocytic and Follicular Thyroid Carcinoma by the 2022 WHO Classification.The Journal of clinical endocrinology and metabolism · 2025Article
- Various genetic alterations observed in both benign and malignant oncocytic (Hürthle cell) neoplasms of the thyroid.CytoJournal · 2025Article
- Clinical and Histopathological Risk Factors for Radioactive Iodine-Refractory Follicular and Oncocytic Thyroid Carcinoma.The Journal of clinical endocrinology and metabolism · 2024Article
- Molecular Markers in Follicular and Oncocytic Thyroid Carcinomas: Clinical Application of Molecular Genetic Testing.Current oncology (Toronto, Ont.) · 2024Article
- Predictive Factors of Radioactive Iodine Therapy Refractoriness in Patients with Differentiated Thyroid Carcinoma.World journal of nuclear medicine · 2024Article
- Comparative Uptake Patterns of Radioactive Iodine and [18F]-Fluorodeoxyglucose (FDG) in Metastatic Differentiated Thyroid Cancers.Journal of clinical medicine · 2024Article
- Article
- Management of radioiodine refractory differentiated thyroid cancer: the Latin American perspective.Reviews in endocrine & metabolic disorders · 2024Review
- Oncocytic cell carcinoma of the thyroid with TERT promoter mutation presenting as asphyxia in an elderly: a case report.Frontiers in endocrinology · 2024Article
- A clinically applicable molecular classification of oncocytic cell thyroid nodules.Endocrine-related cancer · 2023Article
- Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma.Cancer discovery · 2023Article
- Mouse Models to Examine Differentiated Thyroid Cancer Pathogenesis: Recent Updates.International journal of molecular sciences · 2023Review
- Significance of oncocytic features in poorly differentiated thyroid carcinoma - a bi-institutional experience.Virchows Archiv : an international journal of pathology · 2023Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
contextHurthle cell cancer (HCC) is an understudied cancer with poor prognosis.
objectiveOur objective was to elucidate the genomic foundations of HCC. DESIGN AND
settingWe conducted a large-scale integrated analysis of mutations, gene expression profiles, and copy number alterations in HCC at a single tertiary-care cancer institution.
methodsMass spectrometry-based genotyping was used to interrogate hot spot point mutations in the most common thyroid oncogenes: BRAF, RET, NRAS, HRAS, KRAS, PIK3CA, MAP2K1, and AKT1. In addition, common oncogenic fusions of RET and NTRK1 as well as PAX8/PPARγ and AKAP9-BRAF were also assessed by RT-PCR. Global copy number changes and gene expression profiles were determined in the same tumor set as the mutational analyses.
resultsWe report that the mutational, transcriptional, and copy number profiles of HCC were distinct from those of papillary thyroid cancer and follicular thyroid cancer, indicating HCC to be a unique type of thyroid malignancy. Unsupervised hierarchical clustering of gene expression showed the 3 groups of Hurthle tumors (Hurthle cell adenoma [HA], minimally invasive Hurthle cell carcinoma [HMIN], and widely invasive Hurthle cell carcinoma [HWIDE] clustered separately with a marked difference between HWIDE and HA. Global copy number analysis also indicated distinct subgroups of tumors that may arise as HWIDE and HMIN. Molecular pathways that differentiate HA from HWIDE included the PIK3CA-Akt-mTOR and Wnt/β-catenin pathways, potentially providing a rationale for new targets for this type of malignancy.
conclusionsOur data provide evidence that HCC may be a unique thyroid cancer distinct from papillary and follicular thyroid cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.